MBX Biosciences (MBX) Competitors $12.48 +0.15 (+1.18%) As of 07/3/2025 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock MBX vs. TVTX, MESO, GPCR, BGM, CVAC, CALT, DYN, AMPH, CRMD, and AUPHShould you be buying MBX Biosciences stock or one of its competitors? The main competitors of MBX Biosciences include Travere Therapeutics (TVTX), Mesoblast (MESO), Structure Therapeutics (GPCR), BGM Group (BGM), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Dyne Therapeutics (DYN), Amphastar Pharmaceuticals (AMPH), CorMedix (CRMD), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical products" industry. MBX Biosciences vs. Its Competitors Travere Therapeutics Mesoblast Structure Therapeutics BGM Group CureVac Calliditas Therapeutics AB (publ) Dyne Therapeutics Amphastar Pharmaceuticals CorMedix Aurinia Pharmaceuticals Travere Therapeutics (NASDAQ:TVTX) and MBX Biosciences (NYSE:MBX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations. Do analysts rate TVTX or MBX? Travere Therapeutics currently has a consensus target price of $32.14, indicating a potential upside of 114.29%. MBX Biosciences has a consensus target price of $37.50, indicating a potential upside of 200.60%. Given MBX Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe MBX Biosciences is more favorable than Travere Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Travere Therapeutics 0 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.87MBX Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer TVTX or MBX? In the previous week, Travere Therapeutics had 13 more articles in the media than MBX Biosciences. MarketBeat recorded 14 mentions for Travere Therapeutics and 1 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 0.95 beat Travere Therapeutics' score of 0.21 indicating that MBX Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral MBX Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is TVTX or MBX more profitable? MBX Biosciences has a net margin of 0.00% compared to Travere Therapeutics' net margin of -82.88%. MBX Biosciences' return on equity of 0.00% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Travere Therapeutics-82.88% -1,179.73% -41.10% MBX Biosciences N/A N/A N/A Which has higher valuation and earnings, TVTX or MBX? MBX Biosciences has lower revenue, but higher earnings than Travere Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTravere Therapeutics$233.18M5.71-$321.55M-$2.81-5.34MBX BiosciencesN/AN/AN/AN/AN/A SummaryMBX Biosciences beats Travere Therapeutics on 6 of the 9 factors compared between the two stocks. Get MBX Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for MBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBX vs. The Competition Export to ExcelMetricMBX BiosciencesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$416.96M$790.73M$5.54B$20.72BDividend YieldN/A4.84%5.24%3.72%P/E RatioN/A1.3527.4328.09Price / SalesN/A226.97420.7938.30Price / CashN/A23.4436.8922.53Price / BookN/A6.298.044.58Net IncomeN/A-$27.73M$3.18B$986.06M7 Day Performance16.05%1.82%2.88%2.79%1 Month Performance5.19%9.90%3.69%5.46%1 Year PerformanceN/A10.79%36.15%15.06% MBX Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBXMBX Biosciences3.1241 of 5 stars$12.48+1.2%$37.50+200.6%N/A$416.96MN/A0.0036TVTXTravere Therapeutics3.2036 of 5 stars$15.02+3.7%$32.14+114.0%+88.9%$1.34B$273.53M-5.35460Analyst ForecastAnalyst RevisionMESOMesoblast2.3857 of 5 stars$10.37+2.0%$18.00+73.7%+58.6%$1.32B$5.90M0.0080Positive NewsGPCRStructure Therapeutics2.9315 of 5 stars$23.03+4.2%$76.17+230.8%-44.9%$1.32BN/A-26.46136Positive NewsBGMBGM GroupN/A$13.34+1.7%N/AN/A$1.28B$25.10M0.00298CVACCureVac4.6428 of 5 stars$5.35-1.0%$9.00+68.4%+72.9%$1.20B$523.70M5.81880CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180DYNDyne Therapeutics3.5129 of 5 stars$10.35+1.9%$41.87+304.5%-73.5%$1.18BN/A-2.88100AMPHAmphastar Pharmaceuticals4.3742 of 5 stars$24.58-0.4%$32.33+31.5%-39.9%$1.16B$731.97M8.902,028News CoverageCRMDCorMedix2.5934 of 5 stars$16.21-2.1%$16.67+2.8%+181.8%$1.10B$43.47M73.7830Analyst RevisionAUPHAurinia Pharmaceuticals3.117 of 5 stars$8.08+3.2%$11.50+42.4%+38.3%$1.09B$235.13M28.88300Positive News Related Companies and Tools Related Companies Travere Therapeutics Competitors Mesoblast Competitors Structure Therapeutics Competitors BGM Group Competitors CureVac Competitors Calliditas Therapeutics AB (publ) Competitors Dyne Therapeutics Competitors Amphastar Pharmaceuticals Competitors CorMedix Competitors Aurinia Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:MBX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MBX Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MBX Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
